[go: up one dir, main page]

WO2001085209A3 - Treating t-cell mediated diseases by modulating dr6 activity - Google Patents

Treating t-cell mediated diseases by modulating dr6 activity Download PDF

Info

Publication number
WO2001085209A3
WO2001085209A3 PCT/US2001/011735 US0111735W WO0185209A3 WO 2001085209 A3 WO2001085209 A3 WO 2001085209A3 US 0111735 W US0111735 W US 0111735W WO 0185209 A3 WO0185209 A3 WO 0185209A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell mediated
modulating
treating
activity
mediated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/011735
Other languages
French (fr)
Other versions
WO2001085209A2 (en
Inventor
Josef Georg Heuer
Jinqi Liu
Songqing Na
Ho Yeong Song
Derek Di Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US10/257,907 priority Critical patent/US20040043022A1/en
Priority to EP01930475A priority patent/EP1282441A2/en
Priority to AU2001257008A priority patent/AU2001257008A1/en
Publication of WO2001085209A2 publication Critical patent/WO2001085209A2/en
Publication of WO2001085209A3 publication Critical patent/WO2001085209A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Novel methods are provided for the treatment or prevention of T cell mediated conditions in a mammal that comprise administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising at least one DR6 agonist or DR6 antagonist.
PCT/US2001/011735 2000-05-10 2001-04-30 Treating t-cell mediated diseases by modulating dr6 activity Ceased WO2001085209A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/257,907 US20040043022A1 (en) 2001-04-30 2001-04-30 Treating t-cell mediated diseases by modulating dr6 activity
EP01930475A EP1282441A2 (en) 2000-05-10 2001-04-30 Treating t-cell mediated diseases by modulating dr6 activity
AU2001257008A AU2001257008A1 (en) 2000-05-10 2001-04-30 Treating t-cell mediated diseases by modulating dr6 activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20301500P 2000-05-10 2000-05-10
US60/203,015 2000-05-10

Publications (2)

Publication Number Publication Date
WO2001085209A2 WO2001085209A2 (en) 2001-11-15
WO2001085209A3 true WO2001085209A3 (en) 2002-04-04

Family

ID=22752104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011735 Ceased WO2001085209A2 (en) 2000-05-10 2001-04-30 Treating t-cell mediated diseases by modulating dr6 activity

Country Status (3)

Country Link
EP (1) EP1282441A2 (en)
AU (1) AU2001257008A1 (en)
WO (1) WO2001085209A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455825A4 (en) * 2001-12-17 2006-05-31 Lilly Co Eli Treating b-cell mediated diseases by modulating dr6 activity
KR20110089185A (en) 2008-11-25 2011-08-04 바이오겐 아이덱 엠에이 인코포레이티드 Use of DR6 and P75 antagonists to promote survival of nervous system cells
CN102735841B (en) * 2011-04-13 2014-11-05 苏州卫生职业技术学院 Method for detecting content of soluble CD28 in blood of patients suffering Graves disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056892A1 (en) * 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
WO1999015663A1 (en) * 1997-09-26 1999-04-01 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
WO1999043839A1 (en) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
WO2000056862A1 (en) * 1999-03-24 2000-09-28 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056892A1 (en) * 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
WO1999015663A1 (en) * 1997-09-26 1999-04-01 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
WO1999043839A1 (en) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
WO2000056862A1 (en) * 1999-03-24 2000-09-28 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. PAN ET AL.: "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor.", FEBS LETTERS, vol. 431, no. 3, 24 July 1998 (1998-07-24), Amsterdam, The Netherlands, pages 351 - 356, XP002113408 *

Also Published As

Publication number Publication date
WO2001085209A2 (en) 2001-11-15
AU2001257008A1 (en) 2001-11-20
EP1282441A2 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
TNSN07312A1 (en) Combination of organic compounds
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
WO2004034988A3 (en) Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2002043652A3 (en) Anti-proliferative drugs
MXPA02012763A (en) Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus.
WO2006133955A8 (en) Adamts13-comprising compositions having thrombolytic activity
GB0001449D0 (en) Compositions
WO2005016326A3 (en) Analogs of thalidomide as potential angiogenesis inhibitors
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
AR019671A1 (en) USE OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF (+) NORCISAPRIDA OR A PHARMACOLOGICALLY ACCEPTABLE SALT OF THE SAME SUBSTANTIALLY FREE OF ITS (-) STEREOISOMERO, FOR THE PREPARATION OF A MEDICINAL PRODUCT
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MXPA06000705A (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders.
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2005009363A3 (en) Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies
WO2005123192A3 (en) Improving pain treatment with strontium combinations
WO2006061715A3 (en) Methylene inhibitors of matrix metalloproteinase
WO2001085209A3 (en) Treating t-cell mediated diseases by modulating dr6 activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10257907

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001930475

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001930475

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001930475

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP